How Physicians and Oncologists View AI Assistance
The progressive integration of AI within medicine is transforming the way physicians evaluate and monitor disease, enabling earlier detection and improving outcomes and quality of care. Medical practices are increasingly leveraging datasets, algorithms, and other machine learning techniques to identify subtle patterns that might not be discernable to physicians without this technology. These AI tools […]
How Costs Impact Utilization for Hemophilia CGTs
When the FDA approved the first cell and gene therapy (CGT) for hemophilia almost two years ago, it represented a massive leap forward in treating the bleeding disorder. The one-and-done agents offer the promise of a cure, giving patients the prospect of freedom from the disease without regular treatments. Although three hemophilia CGTs are now […]
Expanding Molecular Testing: What Payers and Manufacturers Should Know
Medicine has been trending towards personalization for decades. The growth of individualized medicine and new diagnostic technologies has resulted in drugs that are tailored towards patients’ profile and condition—and are much more effective as a result. These therapies rely on the existence of molecular tests, including genetic testing, predictive and prognostic biomarkers, and companion diagnostics. […]
Asembia Trends: The IRA, High-Cost Drugs and Personalized Care
At the beginning of May, almost 8,000 attendees descended on Las Vegas for Asembia’s AXS24 Summit. While all of the session speakers discussed the future of healthcare in one way or another, MMIT noticed a few common trends about the state of the industry today. If you missed the conference, read on for an overview […]
Solving Access Barriers in Biomarker Testing: 5 Tips for Manufacturers
This article was originally published in Drug Channels. Despite the rapid evolution of personalized medicine, access to genetic testing and next-generation sequencing (NGS) is a challenge—due in no small part to coverage confusion. Physicians struggle to navigate poorly defined testing coverage policies and a fragmented payer and vendor ecosystem, resulting in delayed care for patients […]
Changing Payer Management Dynamics at Play in Oncology
When it comes to the degree of payer management within a therapeutic area, pharma companies are becoming the victim of their own successes. One prime example is the rapid growth of competitive therapies across tumor types, pharmacological classes, and mechanisms of action in oncology. Payers have responded to the launch of more innovative and highly […]
Why Pharma Should Prioritize the Patient Journey: A Survivor’s Story
This article was originally published in PharmaVoice. Many years ago, I became one of the first people to be diagnosed with an ultra-rare vasculitis syndrome, a dangerous inflammation of the small blood vessels. My disease is so rare that I had a much better chance of winning the lottery, but instead, I ended up sick. […]
Treating Hemophilia: The Impact of New Gene Therapies
The CDC estimates that more than 33,000 Americans are living with hemophilia, an inherited bleeding disorder which affects primarily men. Patients with hemophilia have a deficiency of the blood proteins, known as coagulation or clotting factors, that help blood to clot properly. The two most common subtypes are hemophilia A (factor VIII deficiency) and hemophilia […]
Unlocking the Pathway Puzzle: How Biopharma Can Navigate the Clinical Pathways Landscape
This article was originally published in Fierce Pharma. In the realm of oncology, the advent of clinical pathways has gained substantial traction in the past two decades as the increasing cost and complexity of cancer care demanded structured, multidisciplinary, and cost-effective approaches. Pathways have become a critical strategy for both physicians and payers to streamline treatment decision-making, […]
What Pharma Needs From RWD: Top 5 Trends
The explosion of real-world data (RWD) now available to pharma companies can be overwhelming. While many larger manufacturers with their own teams of data analysts have been using RWD for years, smaller manufacturers are just beginning to incorporate RWD into their clinical development and market access strategies. Which data sets do they need, and how […]